EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hospital variation in treatment for synchronous metastatic esophageal and gastric cancer: A nationwide population‐based study in the Netherlands

Julie F M Geerts iD, Pauline A J Vissers iD, Bianca Mostert, Bas P L Wijnhoven, Brigitte C M Haberkorn, Marie-Paule G F Anten, Camiel Rosman, Geert-Jan Creemers, Harm Westdorp, Maurice J C van der Sangen, Rob H A Verhoeven, Grard A P Nieuwenhuijzen

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35491 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Julie F M Geerts und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Stomach Neoplasms, Hospitals. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Care for metastatic esophageal (EC) or gastric cancer (GC) includes a large variety of treatment modalities. Data on treatment variation across centers are unknown. This study investigated treatment variation across hospitals and its effect on overall survival (OS) in the Netherlands by conducting a nationwide retrospective cohort study with population‐based data from the Netherlands Cancer Registry. Patients diagnosed with synchronous metastatic EC/GC between 2015 and 2022 were included. Multilevel logistic regression assessed treatment patterns according to hospital of diagnosis. OS was analyzed using Cox regression analysis after categorizing hospitals into tertiles based on their adjusted odds (low/medium/high) for systemic treatment (chemotherapy, targeted therapy, and immunotherapy). Among 8406 EC and 3871 GC patients, the proportion receiving systemic treatment varied substantially: 19.8%–69.6% for EC and 15.8%–81.3% for GC across hospitals. Hospital of diagnosis was significantly associated with the adjusted probability of receiving systemic treatment ( p < .0001). Ten out of 78 EC (12.8%) and 7 out of 73 (9.6%) GC hospitals had significantly lower systemic treatment probabilities. EC patients with OS ≥4 months diagnosed at hospitals with lower probabilities had significantly worse OS compared to high‐probability hospitals (hazard ratios [HR] 0.87 [0.79–0.95] p = .002). GC patients from low‐probability hospitals had significantly worse OS than from medium‐ (HR 0.86 [0.76–0.96], p = .011) or high‐probability hospitals (HR 0.73 [0.64–0.82], p < .0001). In conclusion, this study showed substantial hospital variation in treatment for metastatic EC and GC. Hospital of diagnosis was not only associated with the probability of receiving systemic treatment but also OS. This reflects the challenge of ensuring equal healthcare access.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsStomach NeoplasmsHospitalsHumansNetherlandsMaleFemaleAgedMiddle AgedRetrospective StudiesRegistriesAged, 80 and overAdultSurvival Rate

Stichwörter der Autor:innen

esophageal cancergastric cancerhospital variationmetastatic

Autor:innen und Institutionen

  • Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands.
  • Department of Surgery, Erasmus Medical Centre, Rotterdam, The Netherlands.
  • Department of Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Department of Research & Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands.
  • Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, The Netherlands.
  • Department of Medical Oncology, Maasstad Hospital, Rotterdam, The Netherlands.

ORCID-Profile: Julie F M Geerts, Pauline A J Vissers

Zitieren

APA

Geerts, J. F. M., Vissers, P. A. J., Mostert, B., Wijnhoven, B. P. L., Haberkorn, B. C. M., Anten, M. G. F., Rosman, C., Creemers, G. J., Westdorp, H., van der Sangen, M. J. C., Verhoeven, R. H. A., & Nieuwenhuijzen, G. A. P. (2025). Hospital variation in treatment for synchronous metastatic esophageal and gastric cancer: A nationwide population‐based study in the Netherlands. International Journal of Cancer. https://doi.org/10.1002/ijc.35491

Vancouver

Geerts JFM, Vissers PAJ, Mostert B, Wijnhoven BPL, Haberkorn BCM, Anten MGF, et al. Hospital variation in treatment for synchronous metastatic esophageal and gastric cancer: A nationwide population‐based study in the Netherlands. International Journal of Cancer. 2025. doi:10.1002/ijc.35491

BibTeX
@article{Geerts2025,
  author = {Geerts, Julie F M and Vissers, Pauline A J and Mostert, Bianca and Wijnhoven, Bas P L and Haberkorn, Brigitte C M and Anten, Marie-Paule G F and Rosman, Camiel and Creemers, Geert-Jan and Westdorp, Harm and van der Sangen, Maurice J C and Verhoeven, Rob H A and Nieuwenhuijzen, Grard A P},
  title = {Hospital variation in treatment for synchronous metastatic esophageal and gastric cancer: A nationwide population‐based study in the Netherlands},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35491}
}
Kostenlos starten →